The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series B | Alive

Total Raised


Last Raised

$11.97M | 4 yrs ago

About Acousia Therapeutics

Acousia Therapeutics is a biotech company that experiments with small molecules for treatment of hearing loss. Sensory hair cells are the key cells for hearing in the inner ear. Acousia`s approach will help to replace lost hair cells by cellular regeneration originating from supporting cells.

Acousia Therapeutics Headquarter Location

Sindelfinger Straße 3

Tubingen, 72070,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Acousia Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Acousia Therapeutics is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Acousia Therapeutics Patents

Acousia Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Audiology
  • Auditory system
  • Ear
patents chart

Application Date

Grant Date


Related Topics




Ion channels, Auditory system, Ear, Prodrugs, Audiology


Application Date


Grant Date



Related Topics

Ion channels, Auditory system, Ear, Prodrugs, Audiology



Latest Acousia Therapeutics News

COMUNICADO: Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085

May 11, 2022

Tübingen, Germany, May 11, 2022 / News Aktuell.- Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person in Boston (MA) from June 20–23, 2022. ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients. Designed to modulate a biologically validated target – the KCNQ4-encoded Kv7.4 potassium channel, which is essential for maintaining auditory function – ACOU085 is being developed for the treatment and prevention of hearing loss for a number of acquired and inherited forms of sensorineural hearing loss. ACOU085 is characterized by a unique dual mode of action, which provides acute functional enhancement and long-term protection for the terminally differentiated sensorineural outer hair cells. “Being invited to share the translational background and progress of our ACOU085 lead program with the hearing loss drug development community at the Inner Ear Therapeutics Summit is an exciting opportunity for us,” says Dr. Jonas Dyhrfjeld-Johnsen, Chief Development Officer at Acousia Therapeutics. “I look forward to stimulating discussions with our peers in Boston.” In addition to receiving an invitation to present “Small Molecule, KCNQ4 Agonist ACOU085 for the Treatment and Prevention of Hearing Loss”, Dr. Dyhrfjeld-Johnsen will also participate as a panelist on the panel discussion “De-risking the Early Development Process: A Robust and Comprehensive Early Development Process Is Essential to Minimize Setbacks Faced in the Clinic” and in the workshop “Mind The Gap: Calling Out the Shortfalls in the Current Inner Ear Therapeutic Development Pathway and Illuminating Solutions”. About Acousia Therapeutics Acousia Therapeutics GmbH is a privately-held, clinical stage biotech company based in Tübingen, Germany. The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss. Acousia Therapeutics develops drugs for local and systemic administration. Contact

Acousia Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Acousia Therapeutics Rank

  • Where is Acousia Therapeutics's headquarters?

    Acousia Therapeutics's headquarters is located at Sindelfinger Straße 3, Tubingen.

  • What is Acousia Therapeutics's latest funding round?

    Acousia Therapeutics's latest funding round is Series B.

  • How much did Acousia Therapeutics raise?

    Acousia Therapeutics raised a total of $14.57M.

  • Who are the investors of Acousia Therapeutics?

    Investors of Acousia Therapeutics include KfW, Boehringer Ingelheim Venture Fund, Creathor Ventures, LBBW Venture Capital, Bregua and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.